On June 2, 2025, Day One Biopharmaceuticals held its Annual Meeting where shareholders elected two directors and approved compensation for executives, with the election of Natalie Holles receiving 81,975,302 votes for and Garry Nicholson receiving 65,553,238 votes for. The appointment of PricewaterhouseCoopers as auditors for 2025 was also ratified with 89,705,033 shares in favor.